form8-k_16917.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549


FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 


Date of Report (Date of earliest event reported):  September 20, 2010
 
 
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)

DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
    

One Boston Scientific Place, Natick, Massachusetts
01760-1537
(Address of principal executive offices)
(Zip code)

Registrant’s telephone number, including area code:   (508) 650-8000
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
 
 
ITEM 8.01. 
OTHER EVENTS.
 
On September 20, 2010, Boston Scientific Corporation announced the signing of a definitive agreement to acquire Asthmatx, Inc., a privately held company. Asthmatx designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. Closing of the transaction is subject to customary conditions and is expected to be completed in the fourth quarter.
 
On September 20, 2010, Boston Scientific Corporation issued a press release announcing the signing of the definitive agreement.  A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
 
 
 

ITEM 9.01. 
FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits

Exhibit
Number
  
Description
     
99.1
   Press release dated September 20, 2010 issued by Boston Scientific Corporation.


 
 
 
 
 
 
 
 
 
- 2 -
 
SIGNATURE


Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  BOSTON SCIENTIFIC CORPORATION  
     
     
       
Date:       September 20, 2010
By:
/s/ Timothy A. Pratt  
   
Timothy A. Pratt
  
   
Executive Vice President, Chief Administrative Officer, General Counsel and Secretary
  
       


 
 
 

 
 
- 3 -
 

INDEX TO EXHIBITS

 

Exhibit
Number
  
Description
     
99.1
  
Press release dated September 20, 2010 issued by Boston Scientific Corporation.


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
- 4 -